1.Hedar AM, Stradner MH, Roessler A, Goswami N. Autoimmune Rheumatic Diseases and Vascular Function: The Concept of Autoimmune Atherosclerosis. J Clin Med. 2021;10(19).
2.Hayden MR. Overview and New Insights into the Metabolic Syndrome: Risk Factors and Emerging Variables in the Development of Type 2 Diabetes and Cerebrocardiovascular Disease. Medicina [Internet]. 2023; 59(3).
3.Gupta L, Thomas J, Ravichandran R, Singh M, Nag A, Panjiyar BK. Inflammation in Cardiovascular Disease: A Comprehensive Review of Biomarkers and Therapeutic Targets. Cureus. 2023;15(9):e45483.
4.Radu AF, Bungau SG. Management of Rheumatoid Arthritis: An Overview. Cells. 2021;10(11).
5.Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55(1):31-55.
6.Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. Journal of the American College of Cardiology. 2020;76(25):2982-3021.
7.Alloubani A, Nimer R, Samara R. Relationship between Hyperlipidemia, Cardiovascular Disease and Stroke: A Systematic Review. Current cardiology reviews. 2021;17(6):e051121189015.
8.Alfaddagh A, Martin SS, Leucker TM, Michos ED, Blaha MJ, Lowenstein CJ, et al. Inflammation and cardiovascular disease: From mechanisms to therapeutics. American journal of preventive cardiology. 2020;4:100130.
9.Griffin BR, Faubel S, Edelstein CL. Biomarkers of Drug-Induced Kidney Toxicity. Therapeutic drug monitoring. 2019;41(2):213-26.
10.Li B, Huang H, Zhao J, Deng X, Zhang Z. Discrepancy in Metabolic Syndrome between Psoriatic Arthritis and Rheumatoid Arthritis: a Direct Comparison of Two Cohorts in One Center. Rheumatology and therapy. 2023;10(1):135-48.
11.Jha BK, Sherpa ML, Imran M, Mohammed Y, Jha LA, Paudel KR, et al. Progress in Understanding Metabolic Syndrome and Knowledge of Its Complex Pathophysiology. Diabetology [Internet]. 2023; 4(2):[134-59 pp.].
12.Sethi JK, Hotamisligil GS. Metabolic Messengers: tumour necrosis factor. Nature Metabolism. 2021;3(10):1302-12.
13.Shi J, Fan J, Su Q, Yang Z. Cytokines and Abnormal Glucose and Lipid Metabolism. 2019;10.
14.Welty FK, Alfaddagh A, Elajami TK. Targeting inflammation in metabolic syndrome. Translational research : the journal of laboratory and clinical medicine. 2016;167(1):257-80.
15.Chait A, den Hartigh LJ. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. 2020;7.
16.Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators of inflammation. 2010;2010.
17.Sigit FS, Tahapary DL, Trompet S, Sartono E, Willems van Dijk K, Rosendaal FR, et al. The prevalence of metabolic syndrome and its association with body fat distribution in middle-aged individuals from Indonesia and the Netherlands: a cross-sectional analysis of two population-based studies. Diabetology & Metabolic Syndrome. 2020;12(1):2.
18.Dehghani A, Molani-Gol R, Mohammadi-Narab M, Norouzy A, Abolhassani MH, Tabatabaee Jabali SM, et al. The prevalence of obesity and overweight among Iranian population: an umbrella systematic review and meta-analysis. BMC public health. 2024;24(1):3377.
19.Saif-Ali R, Kamaruddin NA, Al-Habori M, Al-Dubai SA, Ngah WZW. Relationship of metabolic syndrome defined by IDF or revised NCEP ATP III with glycemic control among Malaysians with Type 2 Diabetes. Diabetol Metab Syndr. 2020;12:67.
20.Han K, Park JB. Clinical implication of fasting glucose and systolic/diastolic blood pressure on the prevalence of periodontitis in non-diabetic and non-hypertensive adults using nationally representative data. Experimental and therapeutic medicine. 2018;16(2):671-8.
21.Hallajzadeh J, Safiri S, Mansournia MA, Khoramdad M, Izadi N, Almasi-Hashiani A, et al. Metabolic syndrome and its components among rheumatoid arthritis patients: A comprehensive updated systematic review and meta-analysis. PloS one. 2017;12(3):e0170361.
22.Inchingolo F, Inchingolo AM, Fatone MC, Avantario P, Del Vecchio G, Pezzolla C, et al. Management of Rheumatoid Arthritis in Primary Care: A Scoping Review. International Journal of Environmental Research and Public Health [Internet]. 2024; 21(6).
23.Farhat H, Irfan H, Muthiah K, Pallipamu N, Taheri S, Thiagaraj SS, et al. Increased Risk of Cardiovascular Diseases in Rheumatoid Arthritis: A Systematic Review. Cureus. 2022;14(12):e32308.
24.Hansildaar R, Vedder D, Baniaamam M, Tausche A-K, Gerritsen M, Nurmohamed MT. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. The Lancet Rheumatology. 2021;3(1):e58-e70.
25.Rezuș E, Macovei LA, Burlui AM, Cardoneanu A, Rezuș C. Ischemic Heart Disease and Rheumatoid Arthritis—Two Conditions, the Same Background. Life [Internet]. 2021; 11(10).
26.Cai W, Tang X, Pang M. Prevalence of Metabolic Syndrome in Patients With Rheumatoid Arthritis: An Updated Systematic Review and Meta-Analysis. Frontiers in medicine. 2022;9:855141.
27.Grzechnik K, Targońska-Stępniak B. Metabolic Syndrome and Rheumatoid Arthritis Activity: An Analysis of Clinical, Laboratory, and Ultrasound Parameters. Nutrients. 2023;15(22).
28.Grzechnik K, Targońska-Stępniak B. Metabolic Syndrome and Rheumatoid Arthritis Activity: An Analysis of Clinical, Laboratory, and Ultrasound Parameters. Nutrients [Internet]. 2023; 15(22).
29.Li L, Feng D, Zeng J, Ye P, Chen Y, Wei D. Association between rheumatoid factor and metabolic syndrome in general population. Diabetology & Metabolic Syndrome. 2022;14(1):165.
30.Nazir S, Jankowski V, Bender G, Zewinger S, Rye K-A, van der Vorst EPC. Interaction between high-density lipoproteins and inflammation: Function matters more than concentration! Advanced Drug Delivery Reviews. 2020;159:94-119.
31.Carmona L, Aurrecoechea E, García de Yébenes MJ. Tailoring Rheumatoid Arthritis Treatment through a Sex and Gender Lens. Journal of clinical medicine. 2023;13(1).
32.Bagheri-Hosseinabadi Z, Moadab F, Abbasifard M. Prevalence and contributing factors of metabolic syndrome in rheumatoid arthritis patients. BMC Endocrine Disorders. 2024;24(1):140.
33.Martemucci G, Khalil M, Di Luca A, Abdallah H, D’Alessandro AG. Comprehensive Strategies for Metabolic Syndrome: How Nutrition, Dietary Polyphenols, Physical Activity, and Lifestyle Modifications Address Diabesity, Cardiovascular Diseases, and Neurodegenerative Conditions. Metabolites [Internet]. 2024; 14(6).
34.Grzechnik K, Targońska-Stępniak B. The pathogenic relationship between metabolic syndrome and rheumatoid arthritis activity. Rheumatology Forum. 2024;10(3):105-9.
35.Abdulla A, Sadida HQ, Jerobin J, Elfaki I, Mir R, Mirza S, et al. Unraveling molecular interconnections and identifying potential therapeutic targets of significance in obesity-cancer link. Journal of the National Cancer Center. 2024.
36.Cheuk Yin W, Becky MYM, Danting Z, Wynn C, Tak Mao C, Desmond YHY. Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: a systematic review and meta-analysis. Lupus Science & Medicine. 2024;11(1):e001152.
37.Gigante A, Iannazzo F, Navarini L, Sgariglia MC, Margiotta DPE, Vaiarello V, et al. Metabolic syndrome and adipokine levels in systemic lupus erythematosus and systemic sclerosis. Clinical rheumatology. 2021;40(10):4253-8.
38.Bello N, Meyers KJ, Workman J, Hartley L, McMahon M. Cardiovascular events and risk in patients with systemic lupus erythematosus: Systematic literature review and meta-analysis. Lupus. 2023;32(3):325-41.
39.Frostegård J. Systemic lupus erythematosus and cardiovascular disease. 2023;293(1):48-62.
40.Semalulu T, Tago A, Zhao K, Tselios K. Managing Cardiovascular Risk in Systemic Lupus Erythematosus: Considerations for the Clinician. ImmunoTargets and therapy. 2023;12:175-86.
41.Henein MY, Vancheri S, Longo G, Vancheri F. The Role of Inflammation in Cardiovascular Disease. International journal of molecular sciences. 2022;23(21).
42.Mosalmanzadeh N, Pence BD. Oxidized Low-Density Lipoprotein and Its Role in Immunometabolism. International journal of molecular sciences [Internet]. 2024; 25(21).
43.Guzmán-Martínez G, Marañón C. Immune mechanisms associated with cardiovascular disease in systemic lupus erythematosus: A path to potential biomarkers. Frontiers in immunology. 2022;13:974826.
44.Ugarte-Gil MF, Mak A, Leong J, Dharmadhikari B, Kow NY, Reátegui-Sokolova C, et al. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci Med. 2021;8(1).
45.Pofi R, Caratti G, Ray DW, Tomlinson JW. Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad? Endocrine reviews. 2023;44(6):975-1011.
46.Mejía-Vilet JM, Ayoub I. The Use of Glucocorticoids in Lupus Nephritis: New Pathways for an Old Drug. 2021;8.
47.Wondafrash DZ, Desalegn TZ, Yimer EM, Tsige AG, Adamu BA, Zewdie KA. Potential Effect of Hydroxychloroquine in Diabetes Mellitus: A Systematic Review on Preclinical and Clinical Trial Studies. Journal of diabetes research. 2020;2020:5214751.
48.Huang SP, DerSarkissian M, Gu YM, Duh MS, Wang MJ, Benson J, et al. Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden. Journal of managed care & specialty pharmacy. 2023;29(4):365-77.
49.Dlamini SN, Lombard Z, Micklesfield LK, Crowther N, Norris SA, Snyman T, et al. Glucocorticoids associate with cardiometabolic risk factors in black South Africans. Endocrine connections. 2021;10(8):873-84.
50.Tsujimae M, Masuda A, Takagi M, Kato T, Nakano R, Fujita K, et al. Relapse and side effects of steroid therapy beyond 3 years in autoimmune pancreatitis: A multicenter retrospective study. Pancreatology. 2024;24(2):223-31.
51.Grimaldi L, Duchemin T, Hamon Y, Buchard A, Benichou J, Abenhaim L, et al. Hydroxychloroquine and Cardiovascular Events in Patients With Systemic Lupus Erythematosus. JAMA network open. 2024;7(8):e2432190.
52.Poznyak AV, Orekhov NA, Churov AV, Starodubtseva IA, Beloyartsev DF, Kovyanova TI, et al. Mitochondrial Dysfunction in Systemic Lupus Erythematosus: Insights and Therapeutic Potential. Diseases (Basel, Switzerland). 2024;12(9).
53.Liang S, Wei Z, Fang H, Guan T. Meta-analysis of effectiveness and safety of glucocorticoid combined with hydroxychloroquine in the treatment of systemic lupus erythematosus rash. International journal of rheumatic diseases. 2023;26(9):1686-96.
54.Sircana MC, Erre GL, Castagna F, Manetti R. Crosstalk between Inflammation and Atherosclerosis in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Is There a Common Basis? Life [Internet]. 2024; 14(6).
55.Azuaga AB, Ramírez J, Cañete JD. Psoriatic Arthritis: Pathogenesis and Targeted Therapies. International journal of molecular sciences. 2023;24(5).
56.Hao Y, Zhu YJ, Zou S, Zhou P, Hu YW, Zhao QX, et al. Metabolic Syndrome and Psoriasis: Mechanisms and Future Directions. Frontiers in immunology. 2021;12:711060.
57.Atzeni F, Gerratana E, Francesco Masala I, Bongiovanni S, Sarzi-Puttini P, Rodríguez-Carrio J. Psoriatic Arthritis and Metabolic Syndrome: Is There a Role for Disease Modifying Anti-Rheumatic Drugs? 2021;8.
58.Jamil M, Aslam R, Patel A, Nadir B, Khan S. Prevalence and Extent of Subclinical Atherosclerosis and Associated Cardiovascular Risk Factors in Adult Patients With Psoriatic Arthritis: A Systematic Review. Cureus. 2021;13(8):e16853.
59.Degboé Y, Koch R, Zabraniecki L, Jamard B, Couture G, Ruidavets JB, et al. Increased Cardiovascular Risk in Psoriatic Arthritis: Results From a Case-Control Monocentric Study. Frontiers in medicine. 2022;9:785719.
60.Atzeni F, Gerratana E, Francesco Masala I, Bongiovanni S, Sarzi-Puttini P, Rodríguez-Carrio J. Psoriatic Arthritis and Metabolic Syndrome: Is There a Role for Disease Modifying Anti-Rheumatic Drugs? Frontiers in medicine. 2021;8:735150.
61.Guan H, Tian J, Wang Y, Niu P, Zhang Y, Zhang Y, et al. Advances in secondary prevention mechanisms of macrovascular complications in type 2 diabetes mellitus patients: a comprehensive review. European Journal of Medical Research. 2024;29(1):152.
62.George MD, Hsu JY, Hennessy S, Chen L, Xie F, Curtis JR, et al. Risk of Serious Infection With Low-dose Glucocorticoids in Patients With Rheumatoid Arthritis: An Instrumental Variable Analysis. Epidemiology (Cambridge, Mass). 2022;33(1):65-74.
63.Yan L, Wang W, Qiu Y, Yu C, Wang R, Li C. Role of glucose metabolism reprogramming in keratinocytes in the link between psoriasis and metabolic syndrome. International Immunopharmacology. 2024;139:112704.
64.Gao X, Li R, Jin T, Tang H. The Association Between Metabolic Syndrome and Prostate Cancer Risk: A Large-Scale Investigation and Study of Chinese. Frontiers in endocrinology. 2022;13:787268.
65.Atzeni F, Gerratana E, Masala I, Bongiovanni S, Sarzi-Puttini P, Rodríguez-Carrio J. Psoriatic Arthritis and Metabolic Syndrome: Is There a Role for Disease Modifying Anti-Rheumatic Drugs? Frontiers in medicine. 2021;8:735150.
66.Grygiel-Górniak B, Skoczek W. Molecular Background and Clinical Implications of Glucose Disorders in Patients with Psoriatic Arthritis. Journal of clinical medicine [Internet]. 2023; 12(18).
67.Aljohani R. Metabolic Syndrome and Its Components in Psoriatic Arthritis. Open access rheumatology : research and reviews. 2022;14:7-16.
68.Su L, Xu C, Huang H, Zhang P, Wang J, Ouyang X, et al. Effects of tumor necrosis factor-alpha inhibitors on lipid profiles in patients with psoriasis: a systematic review and meta-analysis. Frontiers in immunology. 2024;15:1354593.
69.Law L, Lindqvist P, Liv P, Hellman U, Lejon K, Geijer M, et al. Increased carotid intima-media thickness in patients with radiographic axial spondyloarthritis compared to controls and associations with markers of inflammation. Clinical rheumatology. 2024;43(5):1559-70.
70.Yan D, Blauvelt A, Dey AK, Golpanian RS, Hwang ST, Mehta NN, et al. New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies. The Journal of investigative dermatology. 2021;141(10):2328-37.
71.Mehta H, Narang T, Dogra S, Handa S, Hatwal J, Batta A. Cardiovascular Considerations and Implications for Treatment in Psoriasis: An Updated Review. Vascular Health and Risk Management. 2024;20:215-29.
72.Olszewski R, Ćwiklińska K, Maślińska M, Kwiatkowska B. Prevention and risk assessment of cardiovascular events in a population of patients with psoriasis and psoriatic arthritis. Reumatologia. 2022;60(4):266-74.
73.Chen Y, Lin P-H, Freedland SJ, Chi J-T. Metabolic Response to Androgen Deprivation Therapy of Prostate Cancer. Cancers [Internet]. 2024; 16(11).
74.Yang U, Harikrishna A, Preda V, Chen J. Efficacy of multidisciplinary interventions in preventing metabolic syndrome and improving body composition in prostate cancer patients treated with androgen deprivation therapy: A systematic review and meta-analysis. Clinical Nutrition ESPEN. 2023;58:27-49.
75.Yang S, Liu H, Fang X-M, Yan F, Zhang Y. Signaling pathways in uric acid homeostasis and gout: From pathogenesis to therapeutic interventions. International Immunopharmacology. 2024;132:111932.
76.Han T, Chen W, Qiu X, Wang W. Epidemiology of gout - Global burden of disease research from 1990 to 2019 and future trend predictions. Therapeutic advances in endocrinology and metabolism. 2024;15:20420188241227295.
77.Raya-Cano E, Vaquero-Abellán M, Molina-Luque R, De Pedro-Jiménez D, Molina-Recio G, Romero-Saldaña M. Association between metabolic syndrome and uric acid: a systematic review and meta-analysis. Scientific reports. 2022;12(1):18412.
78.Du L, Zong Y, Li H, Wang Q, Xie L, Yang B, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy. 2024;9(1):212.
79.Hansildaar R, Vedder D, Baniaamam M, Tausche AK, Gerritsen M, Nurmohamed MT. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. The Lancet Rheumatology. 2021;3(1):e58-e70.
80.Mao T, He Q, Yang J, Jia L, Xu G. Relationship between gout, hyperuricemia, and obesity-does central obesity play a significant role?-a study based on the NHANES database. Diabetol Metab Syndr. 2024;16(1):24.
81.Du L, Zong Y, Li H, Wang Q, Xie L, Yang B, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):212.
82.Lee Y, Hwang J, Desai SH, Li X, Jenkins C, Kopp JB, et al. Efficacy of Xanthine Oxidase Inhibitors in Lowering Serum Uric Acid in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Journal of clinical medicine. 2022;11(9).
83.Sosa F, Shaban M, Lopez J, Duarte GJ, Jain S, Khizar A, et al. Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular Diseases. Clinical Medicine Insights Cardiology. 2024;18:11795468241239542.
84.Masenga SK, Kabwe LS, Chakulya M, Kirabo A. Mechanisms of Oxidative Stress in Metabolic Syndrome. International journal of molecular sciences [Internet]. 2023; 24(9).
85.Eun Y, Han K, Lee SW, Kim K, Kang S, Lee S, et al. Increased risk of incident gout in young men with metabolic syndrome: A nationwide population-based cohort study of 3.5 million men. 2022;9.
86.Yao T-K, Lee R-P, Wu W-T, Chen I-H, Yu T-C, Yeh K-T. Advances in Gouty Arthritis Management: Integration of Established Therapies, Emerging Treatments, and Lifestyle Interventions. International journal of molecular sciences [Internet]. 2024; 25(19).
87.Costa N, Scavuzzi B, Iriyoda T, Lozovoy M, Alfieri D, Medeiros F, et al. Metabolic syndrome and the decreased levels of uric acid by leflunomide favor redox imbalance in patients with rheumatoid arthritis. Clinical and Experimental Medicine. 2018;18.
88.Njeim R, Pannala SSS, Zaidan N, Habib T, Rajamanuri M, Moussa E, et al. Prevalence of Metabolic Syndrome and Its Association with Cardiovascular Outcomes in Hospitalized Patients with Inflammatory Bowel Disease. Journal of clinical medicine. 2024;13(22).
89.Kuriya B, Schieir O, Valois MF, Pope JE, Boire G, Bessette L, et al. Prevalence and Characteristics of Metabolic Syndrome Differ in Men and Women with Early Rheumatoid Arthritis. ACR open rheumatology. 2019;1(9):535-41.
90.Drosos AA, Venetsanopoulou AA, Pelechas E, Voulgari PV. Exploring Cardiovascular Risk Factors and Atherosclerosis in Rheumatoid Arthritis. European Journal of Internal Medicine. 2024;128:1-9.
91.Baoqi Y, Dan M, Xingxing Z, Xueqing Z, Yajing W, Ke X, et al. Effect of Anti-Rheumatic Drugs on Cardiovascular Disease Events in Rheumatoid Arthritis. Frontiers in cardiovascular medicine. 2021;8:812631.
92.Parker B, Bruce I. The Metabolic Syndrome in Systemic Lupus Erythematosus. Rheumatic diseases clinics of North America. 2010;36:81-97, viii.
93.Corona-Meraz FI, Vázquez-Del Mercado M, Sandoval-García F, Robles-De Anda JA, Tovar-Cuevas AJ, Rosales-Gómez RC, et al. Biomarkers in Systemic Lupus Erythematosus along with Metabolic Syndrome. Journal of clinical medicine. 2024;13(7).
94.Karmacharya P, Ogdie A, Eder L. Psoriatic arthritis and the association with cardiometabolic disease: a narrative review. Therapeutic advances in musculoskeletal disease. 2021;13:1759720x21998279.
95.Vecellio M, Hake VX, Davidson C, Carena MC, Wordsworth BP, Selmi C. The IL-17/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis. Frontiers in immunology. 2020;11:596086.
96.Mao T, He Q, Yang J, Jia L, Xu G. Relationship between gout, hyperuricemia, and obesity—does central obesity play a significant role?—a study based on the NHANES database. Diabetology & Metabolic Syndrome. 2024;16(1):24.
97.Cai R, Li F, Li Y, Li Y, Peng W, Zhao M, et al. Mechanism and use strategy of uric acid-lowering drugs on coronary heart disease. IJC Heart & Vasculature. 2024;53:101434.
98.Mashala DG, Ntimana CB, Seakamela KP, Mashaba RG, Maimela E. Sociodemographic Disparities in the Prevalence of Metabolic Syndrome in Rural South Africa: An Analysis of Gender, Age, and Marital, Employment, and Educational Status. Obesities [Internet]. 2024; 4(4):[480-90 pp.].
99.Özmen M, Yersal Ö, Öztürk S, Soysal D, Köseeoğlu MH. Prevalence of the metabolic syndrome in rheumatoid arthritis. European journal of rheumatology. 2014;1(1):1-4.
100.Gosselt HR, Muller IB, Jansen G, van Weeghel M, Vaz FM, Hazes JMW, et al. Identification of Metabolic Biomarkers in Relation to Methotrexate Response in Early Rheumatoid Arthritis. Journal of personalized medicine. 2020;10(4).